<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia A Meta-analysis</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date>05/17/2022</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MSc</roleName><forename type="first">Willemijn</forename><forename type="middle">J</forename><surname>Jansen</surname></persName>
							<email>willemijn.jansen@maastrichtuniversity.nl</email>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Rik</forename><surname>Ossenkoppele</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Dirk</forename><forename type="middle">L</forename><surname>Knol</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD;</roleName><forename type="first">Betty</forename><forename type="middle">M</forename><surname>Tijms</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Philip</forename><surname>Scheltens</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Frans</forename><forename type="middle">R J</forename><surname>Verhey</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, PhD</roleName><forename type="first">Pieter</forename><forename type="middle">Jelle</forename><surname>Visser</surname></persName>
							<email>pj.visser@maastrichtuniversity.nl</email>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Pauline</forename><surname>Aalten</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Dag</forename><surname>Aarsland</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Daniel</forename><surname>Alcolea</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Myriam</forename><surname>Alexander</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Ina</forename><forename type="middle">S</forename><surname>Almdahl</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Steven</forename><forename type="middle">E</forename><surname>Arnold</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Inês</forename><surname>Baldeiras</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, PhD</roleName><forename type="first">Henryk</forename><surname>Barthel</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, PhD</roleName><forename type="first">Bart</forename><forename type="middle">N M</forename><surname>Van Berckel</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Kristen</forename><surname>Bibeau</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Kaj</forename><surname>Blennow</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">David</forename><forename type="middle">J</forename><surname>Brooks</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Mark</forename><forename type="middle">A</forename><surname>Van Buchem</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Vincent</forename><surname>Camus</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, PhD</roleName><forename type="first">Enrica</forename><surname>Cavedo</surname></persName>
						</author>
						<author>
							<persName><roleName>MSc</roleName><forename type="first">Kewei</forename><surname>Chen</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Gael</forename><surname>Chetelat</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Ann</forename><forename type="middle">D</forename><surname>Cohen</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, PhD;</roleName><forename type="first">Alexander</forename><surname>Drzezga</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, PhD;</roleName><forename type="first">Sebastiaan</forename><surname>Engelborghs</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Anne</forename><forename type="middle">M</forename><surname>Fagan</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Tormod</forename><surname>Fladby</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Adam</forename><forename type="middle">S</forename><surname>Fleisher</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, MAS</roleName><forename type="first">Wiesje</forename><forename type="middle">M</forename><surname>Van Der Flier</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Lisa</forename><surname>Ford</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Stefan</forename><surname>Förster</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Juan</forename><surname>Fortea</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD;</roleName><forename type="first">Nadia</forename><surname>Foskett</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Kristian</forename><forename type="middle">S</forename><surname>Frederiksen</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, PhD</roleName><forename type="first">Yvonne</forename><surname>Freund-Levi</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, PhD</roleName><forename type="first">Giovanni</forename><forename type="middle">B</forename><surname>Frisoni</surname></persName>
						</author>
						<author>
							<persName><roleName>MD;</roleName><forename type="first">Lutz</forename><surname>Froelich</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Tomasz</forename><surname>Gabryelewicz</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">;</forename><surname>Kiran</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Dip</forename><surname>Gill</surname></persName>
						</author>
						<author>
							<persName><roleName>MSc</roleName><forename type="first">Olymbia</forename><surname>Gkatzima</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Estrella</forename><surname>Gómez-Tortosa</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Department of Psychiatry and Neuropsychology</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">School for Mental Health and Neuroscience</orgName>
								<orgName type="institution" key="instit1">Alzheimer Center Limburg</orgName>
								<orgName type="institution" key="instit2">Maastricht University</orgName>
								<address>
									<postBox>PO Box 616</postBox>
									<postCode>6200 MD</postCode>
									<settlement>Maastricht</settlement>
									<country key="NL">the Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia Original Investigation Research</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Dept NVS</orgName>
								<orgName type="department" key="dep2">Center for Alzheimer</orgName>
								<orgName type="department" key="dep3">Karolinska Institutet, and Geriatric Medicine</orgName>
								<orgName type="institution">Translational Alzheimer Neurobiology</orgName>
								<address>
									<settlement>Newberg)</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department">Department of Psychological Medicine</orgName>
								<orgName type="institution">Karolinska University Hospital</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country>Sweden (Nordberg</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department">Institute of Psychiatry</orgName>
								<orgName type="institution">Kings College London</orgName>
								<address>
									<settlement>London</settlement>
									<country>United Kingdom (Perera</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<orgName type="department">Department of Psychiatry and Psychotherapy</orgName>
								<address>
									<settlement>Charité Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="department">German Center for Neurodegenrative Diseases (DZNE)</orgName>
								<orgName type="institution">Peters</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Department of Psychiatry</orgName>
								<orgName type="department" key="dep2">Service of Old Age Psychiatry and Department of Clinical Neurosciences</orgName>
								<orgName type="department" key="dep3">Leenaards Memory Centre</orgName>
								<orgName type="institution">University Hospital of Lausanne</orgName>
								<address>
									<settlement>Lausanne</settlement>
									<country>Switzerland (Popp); Postgraduate</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="department" key="dep1">Institute of Medical Education and Research (PGIMER)</orgName>
								<orgName type="department" key="dep2">Department of Neurology</orgName>
								<orgName type="institution">Nehru Hospital</orgName>
								<address>
									<settlement>Chandigarh</settlement>
									<country>India (Prabhakar</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="department">Turku PET Centre and Division of Clinical Neurosciences Turku</orgName>
								<orgName type="institution" key="instit1">University of Turku</orgName>
								<orgName type="institution" key="instit2">Turku University Hospital</orgName>
								<address>
									<settlement>Turku</settlement>
									<country>Finland (Rinne</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="department">Center for Vital Longevity</orgName>
								<orgName type="institution" key="instit1">University of Texas at Dallas (Rodrigue)</orgName>
								<orgName type="institution" key="instit2">Neurology Service</orgName>
								<orgName type="institution" key="instit3">Universitary Hospital Marqués de Valdecilla</orgName>
								<orgName type="institution" key="instit4">IDIVAL</orgName>
								<address>
									<addrLine>Sanchez-Juan)</addrLine>
									<settlement>Santander</settlement>
									<country>Spain (Rodríguez-Rodríguez</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff12">
								<orgName type="department">Department of Nuclear Medicine and Centre for PET</orgName>
								<orgName type="institution">Austin Health</orgName>
								<address>
									<addrLine>Rowe, Villemagne)</addrLine>
									<settlement>Melbourne</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff13">
								<orgName type="department">Department of Psychiatry and Psychotherapy</orgName>
								<orgName type="laboratory">Neurologie de la Mémoire et du Langage</orgName>
								<orgName type="institution" key="instit1">University Medical Center</orgName>
								<orgName type="institution" key="instit2">Georg-August University</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country>Germany (Rüther, Wiltfang</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff14">
								<orgName type="department">Sektion Gerontopsychiatrie</orgName>
								<orgName type="institution" key="instit1">Centre Hospitalier Sainte-Anne</orgName>
								<orgName type="institution" key="instit2">Université Paris 5</orgName>
								<address>
									<settlement>Paris</settlement>
									<country>France (Sarazin</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff15">
								<orgName type="institution">Universität Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country>Germany (Schröder</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff16">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Eastern Finland and Kuopio University Hospital</orgName>
								<address>
									<settlement>Kuopio</settlement>
									<country>Finland (Herukka, Soininen</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff17">
								<orgName type="department">Department of Geriatrics-Gerontology-Gerontopsychiatry</orgName>
								<orgName type="laboratory">Neurochemistry Laboratory and Biobank</orgName>
								<orgName type="institution">Carol Davila University of Medicine and Pharmacy</orgName>
								<address>
									<settlement>Bucharest</settlement>
									<country>Romania (Spiru</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff18">
								<orgName type="department">Department of Clinical Chemistry</orgName>
								<orgName type="institution" key="instit1">Neuroscience Campus Amsterdam</orgName>
								<orgName type="institution" key="instit2">VU University Medical Center</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country>the Netherlands (Teunissen</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff19">
								<orgName type="department" key="dep1">Departments of Neurology and Laboratory Medicine</orgName>
								<orgName type="department" key="dep2">Donders Institute for Brain, Cognition and Behaviour</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff20">
								<orgName type="department">Radboud Alzheimer Center</orgName>
								<orgName type="institution">Radboud University Medical Center</orgName>
								<address>
									<settlement>Nijmegen, Verbeek, van Waalwijk van Doorn)</settlement>
									<country key="NL">the Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff21">
								<orgName type="department" key="dep1">Danish Dementia Research Center</orgName>
								<orgName type="department" key="dep2">Department of Neurology</orgName>
								<orgName type="laboratory">Clinical Memory Research Unit</orgName>
								<orgName type="institution" key="instit1">Rigshospitalet</orgName>
								<orgName type="institution" key="instit2">University of Copenhagen</orgName>
								<address>
									<addrLine>Waldemar)</addrLine>
									<settlement>Frederiksen</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff22">
								<orgName type="institution" key="instit1">Clinical Sciences Malmö</orgName>
								<orgName type="institution" key="instit2">Lund University</orgName>
								<address>
									<addrLine>Alzheimer Center</addrLine>
									<settlement>Lund</settlement>
									<country>Sweden (Mattsson, Å. K. Wallin</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff23">
								<orgName type="institution">Wroclaw Medical University</orgName>
								<address>
									<settlement>Scinawa</settlement>
									<country>Poland (Zboch</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff24">
								<orgName type="institution" key="instit1">UCL Institute of Neurology</orgName>
								<orgName type="institution" key="instit2">Queen Square</orgName>
								<address>
									<settlement>London</settlement>
									<country>United Kingdom (Zetterberg</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff25">
								<orgName type="department">Department of Imaging and Pathology</orgName>
								<orgName type="laboratory">LANVIE-Laboratory of Neuroimaging of Aging</orgName>
								<orgName type="institution" key="instit1">Memory Clinic</orgName>
								<orgName type="institution" key="instit2">University Hospitals</orgName>
								<orgName type="institution" key="instit3">University of Geneva</orgName>
								<address>
									<settlement>Geneva</settlement>
									<country>Switzerland (Frisoni</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff26">
								<orgName type="institution">Catholic University Leuven</orgName>
								<address>
									<settlement>Leuven, Belgium (Van Laere</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff27">
								<orgName type="department" key="dep1">Department of Psychiatry and Neuropsychology</orgName>
								<orgName type="department" key="dep2">School for Mental Health and Neuroscience</orgName>
								<orgName type="department" key="dep3">Alzheimer Center Limburg</orgName>
								<orgName type="department" key="dep4">Department of Neurology and Alzheimer Center</orgName>
								<orgName type="institution">Maastricht University</orgName>
								<address>
									<addrLine>Visser)</addrLine>
									<settlement>Maastricht, Jansen, Verhey</settlement>
									<country key="NL">the Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff28">
								<orgName type="department">Department of Radiology and Nuclear Medicine</orgName>
								<orgName type="institution" key="instit1">VU University Medical Center</orgName>
								<orgName type="institution" key="instit2">Neuroscience Campus Amsterdam</orgName>
								<address>
									<addrLine>Visser)</addrLine>
									<settlement>Amsterdam, Ossenkoppele, Tijms, Scheltens</settlement>
									<country key="NL">the Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff29">
								<orgName type="institution">VU University Medical Center</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff30">
								<orgName type="department">Department of Neurology, Memory and Aging Center</orgName>
								<orgName type="institution">Neuroscience Campus Amsterdam</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country>the Netherlands (Ossenkoppele</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff31">
								<orgName type="department" key="dep1">San Francisco (Ossenkoppele)</orgName>
								<orgName type="department" key="dep2">Department of Epidemiology and Biostatistics</orgName>
								<orgName type="institution" key="instit1">University of California</orgName>
								<orgName type="institution" key="instit2">Helen Wills Neuroscience Institute</orgName>
								<orgName type="institution" key="instit3">University of California</orgName>
								<address>
									<settlement>Berkeley (Ossenkoppele)</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff32">
								<orgName type="institution">VU University Medical Center</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country>the Netherlands (Knol</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff33">
								<orgName type="department">Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia Original Investigation Research</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia A Meta-analysis</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published">05/17/2022</date>
						</imprint>
					</monogr>
					<idno type="MD5">9141001D3256FAF9E25FF7929D658558</idno>
					<idno type="DOI">10.1001/jama.2015.4668</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:34+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>IMPORTANCE Cerebral amyloid-β aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset.</s><s>Estimates of the prevalence of amyloid pathology in persons without dementia are needed to understand the development of AD and to design prevention studies.</s></p><p><s>OBJECTIVE To use individual participant data meta-analysis to estimate the prevalence of amyloid pathology as measured with biomarkers in participants with normal cognition, subjective cognitive impairment (SCI), or mild cognitive impairment (MCI).</s></p><p><s>DATA SOURCES Relevant biomarker studies identified by searching studies published before April 2015 using the MEDLINE and Web of Science databases and through personal communication with investigators.</s></p><p><s>STUDY SELECTION Studies were included if they provided individual participant data for participants without dementia and used an a priori defined cutoff for amyloid positivity.</s><s>DATA EXTRACTION AND SYNTHESIS Individual records were provided for 2914 participants with normal cognition, 697 with SCI, and 3972 with MCI aged 18 to 100 years from 55 studies.</s><s>MAIN OUTCOMES AND MEASURES Prevalence of amyloid pathology on positron emission tomography or in cerebrospinal fluid according to AD risk factors (age, apolipoprotein E [APOE] genotype, sex, and education) estimated by generalized estimating equations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p><s>The prevalence of amyloid pathology increased from age 50 to 90 years from 10% (95% CI, 8%-13%) to 44% (95% CI, 37%-51%) among participants with normal cognition; from 12% (95% CI, 8%-18%) to 43% (95% CI, 32%-55%) among patients with SCI; and from 27% (95% CI, 23%-32%) to 71% (95% CI, 66%-76%) among patients with MCI.</s><s>APOE-ε4 carriers had 2 to 3 times higher prevalence estimates than noncarriers.</s><s>The age at which 15% of the participants with normal cognition were amyloid positive was approximately 40 years for APOE ε4ε4 carriers, 50 years for ε2ε4 carriers, 55 years for ε3ε4 carriers, 65 years for ε3ε3 carriers, and 95 years for ε2ε3 carriers.</s><s>Amyloid positivity was more common in highly educated participants but not associated with sex or biomarker modality.</s></p><p><s>CONCLUSIONS AND RELEVANCE Among persons without dementia, the prevalence of cerebral amyloid pathology as determined by positron emission tomography or cerebrospinal fluid findings was associated with age, APOE genotype, and presence of cognitive impairment.</s><s>These findings suggest a 20-to 30-year interval between first development of amyloid positivity and onset of dementia.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>As most published studies did not provide prevalence estimates according to age and other risk factors, we asked study contact persons to provide participant-level data or tabulated data according to 10-year age categories and unpublished data if available.</s><s>Tabulated data were converted to participant-level data with the average age in the age category.</s><s>The quality of primary articles from each study was systematically assessed using relevant criteria from the STROBE <ref type="bibr" target="#b42">14</ref> and QUADAS <ref type="bibr" target="#b44">15</ref> guidelines (eTable 1 in the Supplement).</s><s>All participants gave written informed consent to participate.</s><s>Studies were approved by the local ethics committees of the participating centers.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data Collection and Operationalization</head><p><s>Information on study procedures was extracted from the publication or requested from the study contact person and used to create a common set of variables.</s></p><p><s>Cognitive Status, APOE, Sex, and Education Normal cognition was defined as normal scores on cognitive tests, the absence of cognitive complaints for which medical help was sought, or both.</s><s>Subjective cognitive impairment was defined as presence of a cognitive complaint with presentation at a health care facility but normal cognition on tests.</s><s>Mild cognitive impairment was defined according to published criteria. <ref type="bibr" target="#b45">16,</ref><ref type="bibr" target="#b46">17</ref></s><s>These include a decline in memory or another cognitive domain reported by the patient, informant, or both and objectively verified by neuropsychological testing, in combination with no or minimal impairment in activities of daily living and not meeting criteria for dementia.</s><s>Mild cognitive impairment was subclassified as amnestic MCI or nonamnestic MCI when possible.</s><s>Information on APOE-ε4 carrier status (yes/no), APOE genotype, and years of education was retrieved.</s><s>To describe the association of APOE genotype with age, we reported for each genotype the age at which 15% of the participants with normal cognition were amyloid positive as a proxy for first appearance of abnormal amyloid.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Setting and Recruitment</head><p><s>The study setting was classified as clinical if patients presented with cognitive complaints at a health care facility; research if patients were asked to participate in research by recruitment through advertisements or from other hospital departments; population-based if a random sample of the general population was included; or mixed if participants were recruited from a combination of settings.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Amyloid Assessment</head><p><s>Measurement details documented included amyloid tracer and assessment via visual scales or quantitative measures for PET studies and assay used to measure amyloid-β 1-42 levels for CSF studies.</s><s>Positron emission tomography and CSF biomarkers were dichotomized as negative (normal) or positive (abnormal) according to study-specific cutoffs.</s><s>(See eTables 2 and 3 in the Supplement for measurement details.)</s><s>For participants who had both PET and CSF amyloid measures, we selected the first amyloid measure in time.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analysis</head><p><s>We conducted a meta-analysis with individual participant data, in which original research data were sought directly from study contact persons, combined, and reanalyzed centrally.</s><s>Generalized estimating equations (GEEs) were used to estimate the prevalence and odds ratios (ORs).</s><s>Generalized estimating equations allow for analysis of binary correlated data such that participant-level data on the prevalence from all studies could be modeled while simultaneously accounting for the clustering of participants within studies.</s><s>We assumed a logit link function for binary outcome with an exchangeable correlation structure to account for withinstudy correlation.</s><s>Analyses were performed using SPSS version 20.0 (IBM) with the genlin command.</s><s>They were conducted using the total study population unless specified otherwise.</s></p><p><s>The main analyses were performed with cognitive status (normal cognition, SCI, MCI), age, sex, education, and APOE-ε4 genotype as independent variables.</s><s>Age was entered as a continuous measure centered at the median.</s><s>Educational level was dichotomized at the median (high, ≥14 years, vs moderate to low, &lt;14 years).</s><s>Secondary analyses tested associations with biomarker modality, MCI subtype, published vs unpublished studies, setting, and recruitment strategy while adjusting for cognitive status, age, and APOE-ε4 carrier status.</s><s>We tested 2-way and 3-way interactions between variables and age as a quadratic term, and</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>The literature search resulted in 7578 publications; amyloid was assessed by PET in 890 and by CSF in 6688.</s><s>From these, 599 were selected for full-text review.</s><s>We identified 47 studies from the European multicenter projects (Figure <ref type="figure">1</ref>).</s><s>A total of 91 unique studies met inclusion criteria; the authors of 55 studies agreed to share data.</s><s>Contact persons from 54 studies provided participant-level data and 1 provided tabulated data (n = 137).</s><s>Of the 36 studies for which contact persons refused or did not reply, 31 were selected through the literature search and 5 from the European multicenter studies.</s><s>Characteristics of the 31 excluded published studies did not differ from those of the 55 included studies (eTable 4 in the Supplement).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Characteristics</head><p><s>Of the selected studies, 45 were single-center and</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Participant Characteristics</head><p><s>We included 7583 participants from 55 studies, of whom 2914 (38%) had normal cognition, 697 (9%) SCI, and 3972 (52%) MCI.</s><s>Amyloid positivity was assessed with PET for 2370 participants (31%; 1346 normal cognition, 35 SCI, 989 MCI) and with CSF for 5213 participants (69%; 1568 normal cognition, 662 SCI, 2983 MCI).</s><s>Baseline characteristics according to cognitive status are shown in Table <ref type="table" target="#tab_2">1</ref>.</s><s>Participants with missing APOE data did not differ in amyloid positivity and sex from participants with APOE data but more often had limited education (63%) compared with participants who had these data available (48%, χ = 62.5, P &lt; .001).</s><s>Participants with missing sex or education data did not differ in amyloid positivity, sex or education, and APOE-ε4 carrier status from participants with these data.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Prevalence of Amyloid Positivity</head><p><s>Estimated probabilities of amyloid positivity according to cognitive status, APOE-ε4 status, and age are displayed in Figure <ref type="figure" target="#fig_0">2</ref>, Figure <ref type="figure" target="#fig_1">3A</ref> and B, and Table <ref type="table" target="#tab_6">2</ref>. Observed prevalence estimates are shown in Table <ref type="table" target="#tab_5">3</ref>.</s><s>The difference between the observed and predicted prevalence rates was less than 10% in more than 90% of the comparisons indicating good model fit.</s><s>Amyloid positivity was about twice as common in patients with MCI compared with participants with normal cognition (mean difference, 25% [95% CI, 22% to 28%]; P &lt; .001) or SCI (mean difference, 23% [95% CI, 14% to 32%]; P &lt; .001),</s><s>while it did not differ between participants with normal cognition and SCI (mean difference, 2% [95% CI, −6% to 10%]; P = .62).</s><s>Amyloid positivity increased with age in all diagnostic groups.</s><s>APOE-ε4 carriers had 10% to 40% higher absolute prevalence estimates than noncarriers in each diagnostic group (Table <ref type="table" target="#tab_6">2</ref>, Figure <ref type="figure" target="#fig_1">3A and B</ref>).</s><s>At the median age of 70 years, the prevalence estimates were different between all APOE genotypes in participants with normal cognition, except for those of the ε2ε4 and ε3ε4 genotypes, which did not differ from each other (mean difference ε4ε4 vs ε3ε4, 38% [95% CI, 22% to 53%]; P &lt; .001,</s><s>vs ε2ε4, 28% [95% CI, 7% to 49%]; P = .008,</s><s>vs ε3ε3, 60% [95% CI, 44% to 75%]; P &lt; .001,</s><s>vs ε2ε3, 73% [95% CI, 58% to 87%]; P &lt; .001;</s><s>mean difference ε3ε4 vs ε2ε4, 9% [95% CI, −1% to 20%]; P = .08,</s><s>vs ε3ε3, 22% [95% CI, 18% to 26%]; P &lt; .001,</s><s>vs ε2ε3, 35%</s></p><p><s>[95% CI, 29% to 40%]; P &lt; .001;</s><s>mean difference ε2ε4 vs ε3ε3, 31% [95% CI, 21% to 42%]; P &lt; .001,</s><s>vs ε2ε3, 44% [95% CI, 31% to 57%]; P &lt; .001;</s><s>mean difference ε3ε3 vs ε2ε3, 13% [95% CI, 8% to 17%]; P &lt; .001)</s><s>(Figure <ref type="figure" target="#fig_1">3C</ref>).</s></p><p><s>After correction for multiple comparisons, ε2ε4 and ε4ε4 showed no statistically significant difference (P = .08).</s><s>None of the 10 participants with ε2ε2 were amyloid positive.</s><s>APOE genotype was associated with the age at onset of amyloid positivity.</s><s>For example, the age at which 15% of the participants with normal cognition were amyloid positive was approximately 40 years for ε4ε4 carriers, 50 years for ε2ε4 carriers, 55 years for ε3ε4 carriers, 65 years for ε3ε3 carriers,  <ref type="table" target="#tab_10">140 (4.8)  1 (0.1)  1 (0.0)   40-44  28 (1.0)  3 (0.4)  10 (0.3)   45-49  80 (2.7)  12 (1.7)  31 (0.8)   50-54  178 (6.1)  48 (6.9)  113 (2.8)   55-59  258 (8.9)  158 (22.7)  349 (8.8</ref>  <ref type="figure" target="#fig_1">3D</ref>).</s><s>Patients with MCI and the APOE ε2ε2 genotype were not included in the analysis because of the small sample size (n = 5, of whom 1 was amyloid positive).</s><s>The prevalence of amyloid pathology in patients with MCI at age 70 years was 89% (95% CI, 81%-94%) for ε4ε4 carriers, 66% (95% CI, 60%-72%) for ε3ε4 carriers, 57% (95% CI, 35%-76%) for ε2ε4 carriers, 35% (95% CI, 31%-40%) for ε3ε3 carriers, and 25% (95% CI, 19%-32%) for ε2ε3 carriers.</s><s>Table <ref type="table" target="#tab_10">4</ref> shows the ORs for amyloid positivity of the APOE genotypes relative to the ε3ε3 genotype at age 70 years for participants with normal cognition and MCI.</s></p><p><s>The prevalence of amyloid pathology at the mean age was 5% higher (95% CI, 1% to 8%; P = .005)</s><s>in participants with an education above the median (n = 2530) than in those with education below the median (n = 2415) regardless of cognitive status, age, and APOE-ε4 carrier status (eFigure 1 in the Supplement).</s><s>There was no significant association with or interaction between sex and any of the risk factors for amyloid positivity (mean difference, 1% [95% CI, −1% to 3%]; P = .52).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Comparison With Prevalence of AD-Type Dementia</head><p><s>The age-related increase in amyloid positivity in participants with normal cognition paralleled age-specific AD-type dementia prevalence estimates, with an intervening period of about 20 years (Figure <ref type="figure" target="#fig_2">4A</ref>).</s><s>Similarly, APOE genotype-specific estimates of amyloid positivity paralleled APOE genotypespecific lifetime risks of AD-type dementia with a difference of 25 to 30 years (Figure <ref type="figure" target="#fig_2">4B</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Number Needed to Screen</head><p><s>The numbers of participants needed to screen (NNS) to identify 1 amyloid-positive person are displayed according to age, cognitive status, and APOE genotype in eTable 6 in the Supplement.</s><s>The NNS varied from 1.0 (95% CI, 1.0-1.1),</s><s>for persons with normal cognition or MCI who were older than 70 years with the APOE ε4ε4 genotype, to 16.7 (95% CI, 11.1-25.0),</s><s>for persons with normal cognition aged 50 years without an APOE-ε4 allele.</s><s>If APOE genotype is unknown, participants need to be screened for this first.</s><s>The number of participants for whom APOE genotyping needs to be performed to find 1 participant with that particular APOE genotype who is amyloid positive varied between 3.5 (95% CI, 2.8-4.3), for persons with normal cognition aged 90 years without an APOE-ε4 allele, to 89.6 (95% CI, 64.5-129.0),</s><s>for persons with normal cognition aged 50 years with the APOE ε4ε4 genotype.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessment of Study-Related Heterogeneity</head><p><s>In the total study population, the intraclass correlation coefficient for study-related random intercept variance was 0.085, indicating minor heterogeneity among studies.</s><s>Within age, APOE-ε4, and diagnostic subgroups, heterogeneity was not substantial according to the I 2 statistic, except for 2 of 54 subgroups (50%-60% in age group 65-69 years of SCI APOE-ε4 carriers and in age group 75-79 years of MCI APOE-ε4 noncarriers) (eTable 7 in the Supplement).</s></p><p><s>Visual inspection of variability in prevalence estimates across age in studies with at least 50 participants also indicated that between-study variability was small (eFigure 2 in the Supplement).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Post Hoc Analyses</head><p><s>The biomarker used to assess amyloid positivity was not associated with prevalence (mean difference, 0% [95% CI, −7% to 8%]; P = .87)</s><s>for participants with normal cognition or MCI (n = 6885).</s><s>Patients with SCI were excluded because amyloid was measured with PET in only 5% of participants.</s><s>While adjusting for APOE-ε4 carrier status and age, amyloid prevalence at the mean age was higher in patients with amnestic MCI (n = 1405) than in patients with nonamnestic MCI (n = 225, 58% [95% CI, 48% to 67%] vs 47% [95% CI, 35% to 60%], mean difference, 11% [95% CI, 0% to 21%]; P = .03)</s><s>and higher in patients with nonamnestic MCI than in participants with normal cognition (n = 2289, mean difference, 15% [95% CI, 2% to 28%]; P = .03).</s><s>The prevalence  Patients with MCI had 20% to 30% higher prevalence estimates of amyloid positivity than those with normal cognition or SCI, supporting the view that MCI is a risk state for AD. <ref type="bibr" target="#b45">16</ref></s><s>ognitively normal and SCI groups did not differ in amyloid positivity, suggesting that the presence of SCI in a memory clinic population might not be associated with an increased risk for AD.</s><s>Previous studies in other settings showed inconsistent results regarding differences in amyloid positivity between cognitively normal and SCI participants, <ref type="bibr" target="#b49">20,</ref><ref type="bibr" target="#b51">21</ref> indicat- The model for the analyses in panels A and B included age, cognitive status, APOE-ε4 status, an interaction between age and cognitive status, and an interaction between age and APOE-ε4 status as predictors.</s><s>The models for the analyses in panels C and D included age, cognitive status, APOE genotype, an interaction between age and cognitive status, an interaction between age and APOE genotype, and an interaction between cognitive status and APOE genotype as predictors.</s><s>In panel C, none of the 10 participants with ε2ε2 were amyloid positive, and no 95% confidence interval is provided for this group.</s><s>In panel D, data of participants with ε2ε2 are not shown because of the small sample size (n = 5).</s><s>Shading indicates 95% CIs; SCI, subjective cognitive impairment; MCI, mild cognitive impairment.</s></p><p><s>ing that further research is needed on this.</s><s>Patients with nonamnestic MCI had lower prevalence estimates of amyloid positivity than patients with amnestic MCI but higher than participants with normal cognition.</s><s>This suggests that both amnestic MCI and nonamnestic MCI are associated with an increased risk for AD and that this risk is higher for patients with amnestic MCI.</s><s>The observation that a substantial number of patients with MCI were not amyloid positive, even at older age, suggests that the MCI phenotype does not always have AD as underlying pathology.</s><s>Possible non-AD causes in MCI may be hippocampal sclerosis, mild depression, or vascular damage.</s></p><p><s>Age was a risk factor for amyloid positivity, which is in line with the finding that age is an important risk factor for postmortem amyloid load <ref type="bibr" target="#b52">22</ref> and for AD-type dementia, <ref type="bibr" target="#b53">23</ref> as also shown in Figure <ref type="figure" target="#fig_2">4A</ref>.</s><s>The prevalence of amyloid positivity in participants with normal cognition aged 50 to 60 years was somewhat higher than found in an earlier populationbased study that was not included in our analysis. <ref type="bibr" target="#b54">24</ref></s><s>This could relate to differences in recruitment strategy and assessment.</s></p><p><s>Relative to the APOE-ε3 allele, the APOE-ε4 risk allele was associated with a greater risk for amyloid positivity and de-  13.2 (10.4-16.6)</s><s>37.8 (32.0-43.9)</s></p><p><s>21.1 (14.4-29.7)</s><s>11.2 (7.6-16.3)</s><s>33.5 (25.9-42.5)</s><s>42.8 (38.7-47.1)</s><s>30.4  (26.5-34.6)</s><s>63.6 (59.0-68.0)</s><s>70 23.1 (19.5-27.2)   17.1 (14.1-20.6)</s><s>47.9 (42.2-53.7)</s><s>25.3  (17.7-34.8)</s><s>15.5 (11.3-20.9)</s><s>45.0 (36.9-53.</s><s>Abbreviations: APOE, apolipoprotein E; MCI, mild cognitive impairment; SCI, subjective cognitive impairment.</s><s>a The prevalence estimates were generated from generalized estimating equations.</s><s>Amyloid positivity in the total group was modeled using age and cognitive status as predictors.</s><s>Amyloid positivity according to APOE-ε4 status was modeled with age, cognitive status, APOE-ε4 status, an interaction between age and cognitive status, and an interaction between age and APOE-ε4 status.</s><s>creased age at onset, while the APOE-ε2 allele had the opposite associations.</s><s>This is similar to the relation of APOE genotype with the risk for AD-type dementia and age at onset of AD-type dementia as reported in clinical studies <ref type="bibr" target="#b55">25,</ref><ref type="bibr" target="#b56">26</ref> and the APOE genotype-specific lifetime risk for AD as shown in Figure <ref type="figure" target="#fig_2">4B</ref>.</s><s>The high prevalence of amyloid positivity in participants with normal cognition and MCI with ε2ε4 in the present study indicates that the detrimental relation of amyloid positivity with ε4 outweighs the protective association with ε2, in line with clinical AD studies. <ref type="bibr" target="#b57">27</ref></s><s>The OR for amyloid pathology of the APOE genotypes relative to the ε3ε3 genotype was similar to the OR for AD-type dementia in case-control studies. <ref type="bibr" target="#b47">18,</ref><ref type="bibr" target="#b57">27</ref></s><s>The strong association of the APOE genotype with amyloid positivity emphasizes APOE as an important target for treatment studies. <ref type="bibr" target="#b58">28,</ref><ref type="bibr" target="#b59">29</ref></s><s>ighly educated participants had a higher prevalence of amyloid pathology than those with less formal education.</s><s>This may seem in contrast with the finding that high education level is associated with a lower risk for AD-type dementia <ref type="bibr" target="#b60">30</ref> but is in agreement with the cognitive reserve hypothesis. <ref type="bibr" target="#b61">31</ref></s><s>According to this hypothesis, nondemented individuals with a high level of education have a greater cognitive reserve such that they can sustain more amyloid pathology before developing dementia.</s><s>Education itself was not associated with the ex- The prevalence estimates in panel A were estimated from a meta-analysis of 14 studies (eMethods in the Supplement).</s><s>The prevalence estimates in panel B of amyloid positivity in participants with normal cognition are plotted against published lifetime risks for Alzheimer disease (AD)-type dementia by APOE genotype (adapted from Genin et al <ref type="bibr" target="#b47">18</ref>   tent of pathology at postmortem examination <ref type="bibr" target="#b62">32</ref> but might modify the relationship between AD pathology and expression of dementia, 33 resulting in higher amyloid positivity prevalence in nondemented highly educated participants.</s><s>An alternative explanation would be that highly educated persons with amyloid pathology may be overrepresented in study participation or clinical care seeking due to self-selection bias.</s></p><p><s>Our finding that the prevalence of amyloid positivity was the same for men and women is in line with a previous neuropathological study showing no difference in neuritic and diffuse plaque load between men and women. <ref type="bibr">34</ref></s><s>This finding is also in agreement with another earlier study, 35 as is our finding that there was no interaction between sex and APOE-ε4 carrier status on amyloid positivity.</s></p><p><s>Although PET and CSF are thought to measure different types of amyloid-β, 36 we did not find differences in amyloid positivity estimates for PET and CSF biomarkers.</s><s>This is in line with published high concordance rates of 84% to 92% between the 2 biomarkers. <ref type="bibr">37,</ref><ref type="bibr">38</ref></s><s>Also, high levels of agreement have been reported for studies that provided more than 50 participants to our study in whom amyloid was assessed with both PET and CSF. <ref type="bibr">39,</ref><ref type="bibr">40</ref></s><s>e pooled data from a large number of studies, and this may have introduced bias because of differences in the methods underlying amyloid assessment, cutoff definition, participant selection, diagnostic criteria, and other aspects of study design.</s><s>However, in the total study sample; in age, APOE, and diagnostic subgroups; and on visual inspection of studyspecific prevalences over age, there was limited evidence for study-related heterogeneity, which supports the pooling of data from different studies (eFigure 2 and eTable 7 in the Supplement).</s><s>Moreover, the Alzheimer's Association Quality Control program for CSF biomarkers reported that overall concordance for diagnostic classification was high between centers despite analytical variance. <ref type="bibr">41</ref></s><s>We also explored the association of a number of study characteristics with the prevalence in post hoc analyses, but no relation was found.</s><s>An advantage of participant-level analysis over aggregated pooling is that the power to detect subgroup effects is increased, 42 while the risk for ecological bias is decreased. <ref type="bibr">43</ref></s><s> limitation of this study is that our participants with normal cognition were mostly recruited via advertisements, making this sample vulnerable to self-selection bias 44 and restricting generalizability to the general population.</s><s>Participants with SCI and MCI were mostly recruited from clinical settings, rendering them dissimilar from these individuals in the general population.</s><s>Participants with significant comorbid disorders are usually excluded from participation, and studies often used standardized cognitive screens, which also affects generalizability.</s><s>Although MCI was not classified as amnestic or non-amnestic for most participants, our findings indicate that we mostly included amnestic MCI patients because the prevalence estimates in amnestic MCI patients did not differ from those with a broad or unspecified definition of MCI.</s><s>Still, patients with nonamnestic MCI had a lower prevalence than patients with amnestic MCI, suggesting that this is an important distinction to make in future research.</s><s>Moreover, our prevalence estimates are based on cross-sectional data.</s><s>The lifetime risk for individuals without dementia to develop amyloid pathology will be higher than the cross-sectional estimate at any age because amyloid-positive persons may die or progress to dementia at follow-up.</s></p><p><s>This study has several implications for understanding the development of AD.</s><s>The observation that key risk factors for AD-type dementia are also risk factors for amyloid positivity in cognitively normal persons provides further evidence for the hypothesis that amyloid positivity in these individuals reflects early AD.</s><s>6]<ref type="bibr">[47]</ref><ref type="bibr">[48]</ref> Our study also indicates that development of AD pathology can start as early as age 30 years, depending on the APOE genotype.</s><s>Comparison with prevalence and lifetime risk estimates of AD-type dementia suggests a 20-to 30-year interval between amyloid positivity and dementia, implying that there is a large window of opportunity to start preventive treatments.</s><s>Still, the exact interval between the onset of amyloid positivity and onset of AD-type dementia needs to be assessed by long-term follow-up studies because not all persons with amyloid pathology will become demented during their lifetime, <ref type="bibr" target="#b63">49</ref> and not all individuals with a clinical diagnosis of AD-type dementia have amyloid pathology.</s><s>Because of the uncertainty about whether and when an amyloid-positive individual without dementia will develop dementia, amyloid positivity in these individuals should not be equated with impending clinical dementia but rather be seen as a risk state.</s><s>Our prevalence rates can be used as an inexpensive and noninvasive approach to select persons at risk for amyloid positivity.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>Among persons without dementia, the prevalence of cerebral amyloid pathology as determined by PET imaging or CSF findings was associated with age, APOE genotype, and presence of cognitive impairment.</s><s>These findings suggest a 20-to 30year interval between first development of amyloid positivity and onset of dementia.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Association of Age With Prevalence Estimates of Amyloid Positivity According to Cognitive Status 100</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure 3. Association of Age With Prevalence Estimates of Amyloid Positivity According to Cognitive Status and Apolipoprotein E (APOE) Genotype</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 4 .</head><label>4</label><figDesc><div><p><s>Figure 4. Comparison of the Prevalence of Amyloid Positivity With the Prevalence of and Lifetime Risks for Alzheimer Disease-Type Dementia</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc><div><p><s>Figure 1.</s><s>Flow Diagram of Literature Search and Study Selection</s></p></div></figDesc><table><row><cell>7578 Records identified through</cell><cell></cell></row><row><cell>database search</cell><cell></cell></row><row><cell cols="2">6979 Excluded based on review of title</cell></row><row><cell>and abstract</cell><cell></cell></row><row><cell cols="2">3701 Other topic, method, or design</cell></row><row><cell cols="2">1760 Duplicates</cell></row><row><cell cols="2">618 Included patients with dementia</cell></row><row><cell cols="2">or other diseases</cell></row><row><cell cols="2">601 Review, opinion, case study, book,</cell></row><row><cell cols="2">or abstract only</cell></row><row><cell cols="2">299 Animal study</cell></row><row><cell>599 Full-text articles assessed for eligibility</cell><cell>47 Studies identified from 2 European multicenter collaborative projects a</cell></row><row><cell cols="2">555 Studies excluded after full review</cell></row><row><cell>533 Duplicates</cell><cell></cell></row><row><cell cols="2">7 Included patients with neurological</cell></row><row><cell cols="2">or psychiatric diseases</cell></row><row><cell cols="2">6 Biomarker cutoff determined using</cell></row><row><cell cols="2">population under study</cell></row><row><cell cols="2">3 No biomarker cutoff available</cell></row><row><cell cols="2">3 Full text not available</cell></row><row><cell cols="2">1 Amyloid not measured in patients</cell></row><row><cell cols="2">without dementia</cell></row><row><cell cols="2">1 No clear diagnosis</cell></row><row><cell>1 Pilot study</cell><cell></cell></row><row><cell>91 Unique studies identified</cell><cell></cell></row><row><cell>80 Published studies</cell><cell></cell></row><row><cell>11 Unpublished studies</cell><cell></cell></row><row><cell cols="2">36 Study contacts did not provide</cell></row><row><cell cols="2">individual data or did not respond</cell></row><row><cell cols="2">31 Published studies</cell></row><row><cell cols="2">5 Unpublished studies</cell></row><row><cell></cell><cell>a The European Medical Information</cell></row><row><cell>55 Studies included in individual</cell><cell>Framework-Alzheimer Disease</cell></row><row><cell>participant meta-analysis (n = 8694 participants)</cell><cell>(EMIF-AD) and Biomarkers for Alzheimer Disease and Parkinson</cell></row><row><cell></cell><cell>Disease (BIOMARKAPD) projects.</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Baseline Study Participant Characteristics</s></p></div></figDesc><table><row><cell></cell><cell>Normal Cognition</cell><cell>SCI</cell><cell>MCI</cell></row><row><cell>Characteristic</cell><cell>(n = 2914)</cell><cell>(n = 697)</cell><cell>(n = 3972)</cell></row><row><cell>Age</cell><cell>(n = 2914)</cell><cell>(n = 697)</cell><cell>(n = 3971)</cell></row><row><cell>Mean (SD), y</cell><cell>66.8 (13.2)</cell><cell>64.2 (8.0)</cell><cell>70.2 (8.7)</cell></row><row><cell>Age groups, No. (%), y</cell><cell></cell><cell></cell><cell></cell></row><row><cell>&lt;40</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head></head><label></label><figDesc><div><p><s>The prevalence estimates were generated from generalized estimating equations.</s><s>The model included age and cognitive status as predictors.</s><s>Shading indicates 95% CIs; SCI, subjective cognitive impairment; MCI, mild cognitive impairment.</s></p></div></figDesc><table><row><cell>Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia</cell><cell>Original Investigation Research</cell></row><row><cell cols="2">jama.com patients diagnosed using a broad or unspecified definition of MCI (n = 1487, mean difference, 3% [95% CI, −6% to 13%]; P = .51). Prevalence estimates did not differ for published and unpublished studies (eTable 8 in the Supplement). The prevalence in participants with normal cognition recruited via advertisements (n = 1868) was similar to that of partici-pants recruited from hospital departments (n = 305, mean (Reprinted) JAMA May 19, 2015 Volume 313, Number 19 did not differ between amnestic MCI (n = 1405) and MCI 90 years, about 40% of the APOE-ε4 noncarriers and more than 80% of APOE-ε4 carri-ers with normal cognition were amyloid positive. Amyloid positivity was associated with education but not with sex or biomarker modality. The age-related prevalence of amyloid positivity in participants with normal cognition paralleled the age-related prevalence of AD-type dementia in the gen-eral population in an APOE genotype-specific way with a difference, 4% [95% CI, −13% to 21%]; P = .96). time lag of 20 to 30 years.</cell></row></table><note><p><s>DiscussionThis amyloid biomarker study including individuals without dementia provides prevalence estimates of amyloid pathology over an age range of 18 to 100 years for persons with normal cognition, SCI, and MCI.</s><s>The age at onset of amyloid positivity was associated with cognitive status and the APOE genotype.</s><s>At age</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Observed Probabilities of Amyloid Positivity a</s></p></div></figDesc><table><row><cell></cell><cell cols="2">Normal Cognition</cell><cell></cell><cell>SCI</cell><cell></cell><cell></cell><cell>MCI</cell><cell></cell><cell></cell></row><row><cell>Age Group</cell><cell>Total</cell><cell>APOE-ε4−</cell><cell>APOE-ε4+</cell><cell>Total</cell><cell>APOE-ε4−</cell><cell>APOE-ε4+</cell><cell>Total</cell><cell>APOE-ε4−</cell><cell>APOE-ε4+</cell></row><row><cell>47.5-52.4 y</cell><cell>13.2</cell><cell>7.9</cell><cell>17.2</cell><cell>19.2</cell><cell>0.0</cell><cell>0.0</cell><cell>25.0</cell><cell>19.4</cell><cell>44.4</cell></row><row><cell></cell><cell>(15/114)</cell><cell>(5/63)</cell><cell>(5/29)</cell><cell>(5/26)</cell><cell>(0/8)</cell><cell>(0/8)</cell><cell>(16/64)</cell><cell>(7/36)</cell><cell>(8/18)</cell></row><row><cell>52.5-57.4 y</cell><cell>15.3</cell><cell>6.9</cell><cell>23.1</cell><cell>10.6</cell><cell>8.3</cell><cell>7.3</cell><cell>26.6</cell><cell>22.0</cell><cell>53.8</cell></row><row><cell></cell><cell>(38/249)</cell><cell>(8/116)</cell><cell>(15/65)</cell><cell>(12/113)</cell><cell>(4/48)</cell><cell>(3/41)</cell><cell>(78/293)</cell><cell>(24/109)</cell><cell>(42/78)</cell></row><row><cell>57.5-62.4 y</cell><cell>12.1</cell><cell>10.0</cell><cell>26.1</cell><cell>16.9</cell><cell>5.2</cell><cell>35.2</cell><cell>39.1</cell><cell>30.4</cell><cell>51.4</cell></row><row><cell></cell><cell>(36/296)</cell><cell>(16/160)</cell><cell>(12/46)</cell><cell>(29/171)</cell><cell>(5/96)</cell><cell>(19/54)</cell><cell>(181/463)</cell><cell>(58/191)</cell><cell>(95/185)</cell></row><row><cell>62.5-67.4 y</cell><cell>22.6</cell><cell>13.4</cell><cell>40.6</cell><cell>16.8</cell><cell>4.5</cell><cell>30.4</cell><cell>45.5</cell><cell>27.7</cell><cell>67.1</cell></row><row><cell></cell><cell>(110/485)</cell><cell>(31/232)</cell><cell>(54/133)</cell><cell>(24/143)</cell><cell>(3/66)</cell><cell>(14/46)</cell><cell>(303/666)</cell><cell>(74/267)</cell><cell>(171/255)</cell></row><row><cell>67.5-72.4 y</cell><cell>24.1</cell><cell>17.1</cell><cell>40.7</cell><cell>26.0</cell><cell>16.1</cell><cell>42.9</cell><cell>54.5</cell><cell>35.0</cell><cell>77.1</cell></row><row><cell></cell><cell>(128/530)</cell><cell>(50/292)</cell><cell>(55/135)</cell><cell>(32/123)</cell><cell>(9/56)</cell><cell>(12/28)</cell><cell>(461/845)</cell><cell>(104/297)</cell><cell>(272/353)</cell></row><row><cell>72.5-77.4 y</cell><cell>32.2</cell><cell>23.3</cell><cell>61.3</cell><cell>44.0</cell><cell>25.0</cell><cell>59.3</cell><cell>57.2</cell><cell>44.4</cell><cell>79.1</cell></row><row><cell></cell><cell>(164/510)</cell><cell>(70/301)</cell><cell>(65/106)</cell><cell>(33/75)</cell><cell>(7/28)</cell><cell>(16/27)</cell><cell>(494/864)</cell><cell>(154/347)</cell><cell>(250/316)</cell></row><row><cell>77.5-82.4 y</cell><cell>42.0</cell><cell>35.1</cell><cell>65.5</cell><cell>31.8</cell><cell>33.3</cell><cell></cell><cell>62.1</cell><cell>49.2</cell><cell>86.9</cell></row><row><cell></cell><cell>(111/264)</cell><cell>(60/171)</cell><cell>(36/55)</cell><cell>(7/22)</cell><cell>(3/9)</cell><cell></cell><cell>(323/520)</cell><cell>(117/238)</cell><cell>(153/176)</cell></row><row><cell>82.5-87.4 y</cell><cell>49.0</cell><cell>41.7</cell><cell>76.5</cell><cell>57.1</cell><cell>50.0</cell><cell></cell><cell>60.3</cell><cell>51.4</cell><cell>81.9</cell></row><row><cell></cell><cell>(103/210)</cell><cell>(55/132)</cell><cell>(39/51)</cell><cell>(8/14)</cell><cell>(4/8)</cell><cell></cell><cell>(135/224)</cell><cell>(57/111)</cell><cell>(59/72)</cell></row><row><cell>87.5-92.4 y</cell><cell>51.0</cell><cell>42.9</cell><cell>87.5</cell><cell></cell><cell></cell><cell></cell><cell>61.4</cell><cell>58.5</cell><cell>100.0</cell></row><row><cell></cell><cell>(25/49)</cell><cell>(15/35)</cell><cell>(7/8)</cell><cell></cell><cell></cell><cell></cell><cell>(35/57)</cell><cell>(24/41)</cell><cell>(7/7)</cell></row><row><cell cols="5">Abbreviations: APOE, apolipoprotein E; MCI, mild cognitive impairment;</cell><cell cols="5">subgroup). No estimates were provided if the age group included</cell></row><row><cell cols="3">SCI, subjective cognitive impairment.</cell><cell></cell><cell></cell><cell cols="2">&lt;5 participants.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="5">a Data are observed probabilities in % (No. amyloid positive/No. total</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Prevalence Estimates of Amyloid Positivity According to Age, Cognitive Status, and APOE-ε4 Carrier Status a</s></p></div></figDesc><table><row><cell></cell><cell cols="2">Normal Cognition, % (95% CI)</cell><cell></cell><cell>SCI, % (95% CI)</cell><cell></cell><cell></cell><cell>MCI, % (95% CI)</cell><cell></cell><cell></cell></row><row><cell cols="2">Age, y Total</cell><cell>APOE-ε4−</cell><cell>APOE-ε4+</cell><cell>Total</cell><cell>APOE-ε4−</cell><cell>APOE-ε4+</cell><cell>Total</cell><cell>APOE-ε4−</cell><cell>APOE-ε4+</cell></row><row><cell>50</cell><cell>10.4</cell><cell>5.7</cell><cell>14.9</cell><cell>11.6</cell><cell>3.9</cell><cell>10.6</cell><cell>26.9</cell><cell>18.7</cell><cell>40.0</cell></row><row><cell></cell><cell>(8.1-13.3)</cell><cell>(3.6-8.9)</cell><cell>(10.2-21.2)</cell><cell>(7.3-17.8)</cell><cell>(1.9-7.8)</cell><cell>(6.2-17.5)</cell><cell>(22.5-31.7)</cell><cell>(14.2-24.2)</cell><cell>(33.2-47.2)</cell></row><row><cell>55</cell><cell>12.9</cell><cell>7.6</cell><cell>20.9</cell><cell>14.2</cell><cell>5.6</cell><cell>16.1</cell><cell>31.8</cell><cell>22.2</cell><cell>47.9</cell></row><row><cell></cell><cell>(10.3-16.0)</cell><cell>(5.2-11.0)</cell><cell>(15.5-27.5)</cell><cell>(9.3-21.2)</cell><cell>(3.1-10.0)</cell><cell>(10.4-24.0)</cell><cell>(27.5-36.4)</cell><cell>(17.8-27.3)</cell><cell>(41.7-54.2)</cell></row><row><cell>60</cell><cell>15.8</cell><cell>10.0</cell><cell>28.6</cell><cell>17.4</cell><cell>8.0</cell><cell>23.7</cell><cell>37.1</cell><cell>26.1</cell><cell>55.9</cell></row><row><cell></cell><cell>(12.9-19.1)</cell><cell>(7.4-13.5)</cell><cell>(22.9-35.1)</cell><cell>(11.6-25.2)</cell><cell>(4.9-12.7)</cell><cell>(16.9-32.2)</cell><cell>(32.9-41.6)</cell><cell>(21.9-30.7)</cell><cell>(50.5-61.2)</cell></row><row><cell>65</cell><cell>19.2</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>(16.0-22.9)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_8"><head></head><label></label><figDesc><div><p><s>Table 3 displays the number of participants and observed probabilities of amyloid positivity per age subgroup.</s><s>No estimate was provided if the 5-year range around the indicated column age included no participants.</s><s>b No participants available with the exact age; prevalence estimated at nearest age.</s></p></div></figDesc><table><row><cell>Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia</cell><cell>Original Investigation Research</cell></row><row><cell>jama.com</cell><cell>(Reprinted) JAMA May 19, 2015 Volume 313, Number 19</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_9"><head></head><label></label><figDesc><div><p><s>).</s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_10"><head>Table 4 .</head><label>4</label><figDesc><div><p><s>Odds Ratios for the Association Between APOE Genotype and Amyloid Positivity at Age 70 Years a The ORs were generated from generalized estimating equations separately in participants with normal cognition and MCI.</s><s>The models included age, APOE genotype, an interaction between age and APOE genotype, and a quadratic age term in the normal cognition model as predictors.</s><s>P values represent the significance of the OR for amyloid positivity compared with the ε3ε3 genotype.</s><s>The ε2ε2 genotype was excluded because of the small number of participants in this group.</s></p></div></figDesc><table><row><cell></cell><cell>APOE Genotype</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>ε3ε3</cell><cell>ε2ε3</cell><cell>ε2ε4</cell><cell>ε3ε4</cell><cell>ε4ε4</cell></row><row><cell>Normal cognition</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>OR (95% CI)</cell><cell>1 [Reference]</cell><cell>0.34 (0.23-0.51)</cell><cell>4.29 (2.67-6.90)</cell><cell>2.94 (2.34-3.70)</cell><cell>18.76 (5.47-64.37)</cell></row><row><cell>P value</cell><cell></cell><cell>&lt;.001</cell><cell>&lt;.001</cell><cell>&lt;.001</cell><cell>&lt;.001</cell></row><row><cell>No. amyloid positive (%)</cell><cell>275 (22.4)</cell><cell>22 (8.6)</cell><cell>17 (41.5)</cell><cell>213 (40.1)</cell><cell>45 (69.2)</cell></row><row><cell>MCI</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>OR (95% CI)</cell><cell>1 [Reference]</cell><cell>0.59 (0.48-0.73)</cell><cell>2.38 (0.98-5.81)</cell><cell>3.52 (2.73-4.55)</cell><cell>14.50 (8.14-25.81)</cell></row><row><cell>P value</cell><cell></cell><cell>&lt;.001</cell><cell>.06</cell><cell>&lt;.001</cell><cell>&lt;.001</cell></row><row><cell>No. amyloid positive (%)</cell><cell>490 (38.7)</cell><cell>57 (27.0)</cell><cell>35 (56.5)</cell><cell>666 (67.2)</cell><cell>261 (86.7)</cell></row><row><cell cols="3">Abbreviations: APOE, apolipoprotein E; OR, odds ratio; MCI, mild cognitive</cell><cell></cell><cell></cell><cell></cell></row><row><cell>impairment.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>a</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">JAMA May 19, 2015 Volume 313, Number 19 (Reprinted) jama.com Copyright 2015 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 05/17/2022</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Copyright 2015 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 05/17/2022</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0" />
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" />			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Md; Timo</forename><surname>Mark Forrest Gordon</surname></persName>
		</author>
		<author>
			<persName><surname>Grimmer</surname></persName>
		</author>
		<imprint>
			<pubPlace>MD, PhD</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<author>
			<persName><forename type="first">Harald</forename><surname>Hampel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd; Lucrezia</forename><surname>Md</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Hausner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd; Sabine</forename><surname>Hellwig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Md; Sanna-Kaisa</forename><surname>Herukka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">PhD; Helmut Hildebrandt, PhD; Lianna Ishihara</title>
				<imprint>
			<publisher>PhD</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">William</forename><forename type="middle">J</forename><surname>Jagust</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Md; Peter</forename><surname>Johannsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Phd; Ramesh</forename><surname>Kandimalla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd; Elisabeth</forename><surname>Kapaki</surname></persName>
		</author>
		<imprint>
			<pubPlace>MD, PhD</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<author>
			<persName><forename type="first">Aleksandra</forename><surname>Klimkowicz-Mrowiec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Phd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">;</forename><surname>William</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Klunk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd; Sebastian</forename><surname>Md</surname></persName>
		</author>
		<author>
			<persName><surname>Köhler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd; Johannes</forename><surname>Phd; Norman Koglin</surname></persName>
		</author>
		<author>
			<persName><surname>Kornhuber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Md; Milica</surname></persName>
		</author>
		<author>
			<persName><surname>Kramberger</surname></persName>
		</author>
		<author>
			<persName><surname>Md</surname></persName>
		</author>
		<author>
			<persName><surname>Phd; Koen Van Laere</surname></persName>
		</author>
		<author>
			<persName><surname>Md</surname></persName>
		</author>
		<author>
			<persName><surname>Phd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Drsc; Susan</surname></persName>
		</author>
		<author>
			<persName><surname>Landau</surname></persName>
		</author>
		<title level="m">PhD; Dong Young</title>
				<meeting><address><addrLine>Lee, MD, PhD; EdD; MSc</addrLine></address></meeting>
		<imprint>
			<publisher>Viviana Lisetti</publisher>
		</imprint>
	</monogr>
	<note>Mony de Leon</note>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Alberto</forename><surname>Lleó</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd; Karine</forename><surname>Md</surname></persName>
		</author>
		<author>
			<persName><surname>Madsen</surname></persName>
		</author>
		<imprint>
			<pubPlace>MD, PhD</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Wolfgang</forename><surname>Maier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd; Jan</forename><surname>Md</surname></persName>
		</author>
		<author>
			<persName><surname>Marcusson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd</forename><surname>Md</surname></persName>
		</author>
		<imprint>
			<pubPlace>Niklas Mattsson, MD, PhD; Mendonça, MD, PhD; Olga Meulenbroek, PhD</pubPlace>
		</imprint>
	</monogr>
	<note>Alexandre de</note>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">T</forename><surname>Philipp</surname></persName>
		</author>
		<author>
			<persName><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><surname>Md</surname></persName>
		</author>
		<author>
			<persName><forename type="first">;</forename><surname>Phd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mark</surname></persName>
		</author>
		<author>
			<persName><surname>Mintun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Md; Vincent</forename><surname>Md</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Md; José Luis</forename><surname>Mok</surname></persName>
		</author>
		<author>
			<persName><surname>Molinuevo</surname></persName>
		</author>
		<imprint>
			<pubPlace>MD, PhD</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Hanne</surname></persName>
		</author>
		<author>
			<persName><surname>Møllergård</surname></persName>
		</author>
		<author>
			<persName><forename type="first">;</forename><surname>Phd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>John</surname></persName>
		</author>
		<author>
			<persName><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><surname>Md; Barbara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Mroczko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd; Stefan</forename><surname>Van Der Mussele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">;</forename><surname>Phd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Duk</surname></persName>
		</author>
		<author>
			<persName><surname>Na</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd</forename><surname>Md</surname></persName>
		</author>
		<imprint>
			<publisher>Agneta</publisher>
			<pubPlace>Newberg, MD, PhD; Nordberg, MD, PhD</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Arto Nordlund</title>
		<imprint/>
	</monogr>
	<note type="report_type">PhD</note>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Gerald</forename><forename type="middle">P</forename><surname>Novak</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">George</forename><forename type="middle">P</forename><surname>Paraskevas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd; Lucilla</forename><surname>Md</surname></persName>
		</author>
		<author>
			<persName><surname>Parnetti</surname></persName>
		</author>
		<imprint>
			<pubPlace>MD, PhD</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Gayan</forename><surname>Perera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd; Oliver</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Md; Julius</forename><surname>Popp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Md; Sudesh</forename><surname>Prabhakar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Phd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">;</forename><surname>Gil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rabinovici</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G B</forename><surname>Md; Inez</surname></persName>
		</author>
		<author>
			<persName><surname>Ramakers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Msc; Catarina Resende De</forename><surname>Phd; Lorena Rami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Oliveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">;</forename><surname>Phd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Juha</surname></persName>
		</author>
		<author>
			<persName><surname>Rinne</surname></persName>
		</author>
		<imprint>
			<pubPlace>MD, PhD</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Karen</forename><forename type="middle">M</forename><surname>Rodrigue</surname></persName>
		</author>
		<author>
			<persName><surname>Phd; Eloy Rodríguez-Rodríguez</surname></persName>
		</author>
		<imprint>
			<pubPlace>MD, PhD</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Catherine</forename><forename type="middle">M</forename><surname>Roe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd</forename></persName>
		</author>
		<imprint>
			<pubPlace>Uros Rot, MD, PhD</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Christopher</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Rowe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd; Eckart</forename><surname>Rüther</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Phd; Osama</forename><surname>Sabri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Phd; Páscual</forename><surname>Sanchez-Juan</surname></persName>
		</author>
		<imprint>
			<pubPlace>MD, PhD</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Isabel</forename><surname>Santana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd; Marie</forename><surname>Md</surname></persName>
		</author>
		<author>
			<persName><surname>Sarazin</surname></persName>
		</author>
		<imprint>
			<pubPlace>MD, PhD</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Johannes</forename><surname>Schröder</surname></persName>
		</author>
		<author>
			<persName><surname>Md</surname></persName>
		</author>
		<author>
			<persName><surname>Phd; Christin</surname></persName>
		</author>
		<author>
			<persName><surname>Schütte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">;</forename><surname>Msc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sang</surname></persName>
		</author>
		<author>
			<persName><surname>Seo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd; Femke</forename><surname>Md</surname></persName>
		</author>
		<author>
			<persName><surname>Soetewey</surname></persName>
		</author>
		<imprint>
			<pubPlace>MSc</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Hilkka</forename><surname>Soininen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd; Luiza</forename><surname>Md</surname></persName>
		</author>
		<author>
			<persName><surname>Spiru</surname></persName>
		</author>
		<imprint>
			<pubPlace>MD, PhD</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Hanne Struyfs</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Charlotte</forename><forename type="middle">E</forename><surname>Teunissen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Magda</forename><surname>Tsolaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd; Rik</forename><surname>Md</surname></persName>
		</author>
		<author>
			<persName><surname>Vandenberghe</surname></persName>
		</author>
		<imprint>
			<pubPlace>MD, PhD</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Marcel</forename><forename type="middle">M</forename><surname>Verbeek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">;</forename><surname>Phd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Victor</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Stephanie</surname></persName>
		</author>
		<author>
			<persName><surname>Vos</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>PhD</note>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Linda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Msc; Gunhild</forename><surname>Van Waalwijk Van Doorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Waldemar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dmsc; Anders</forename><surname>Wallin</surname></persName>
		</author>
		<imprint>
			<pubPlace>MD, PhD</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">K</forename><surname>Åsa</surname></persName>
		</author>
		<author>
			<persName><surname>Wallin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd; Jens</forename><surname>Md</surname></persName>
		</author>
		<author>
			<persName><surname>Wiltfang</surname></persName>
		</author>
		<imprint>
			<pubPlace>MD, PhD</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">David</forename><forename type="middle">A</forename><surname>Wolk</surname></persName>
		</author>
		<author>
			<persName><surname>Md; Marzena</surname></persName>
		</author>
		<author>
			<persName><surname>Zboch</surname></persName>
		</author>
		<imprint>
			<pubPlace>MD, PhD</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<title level="m" type="main">REFERENCES 1. World Health Organization</title>
		<author>
			<persName><forename type="first">Henrik</forename><surname>Zetterberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Phd</forename><surname>Md</surname></persName>
		</author>
		<ptr target="http://www.who.int/mental_health/publications/dementia_report_2012/en/" />
		<imprint>
			<date type="published" when="2015-04-27">Accessed April 27. 2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Bateman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Benzinger</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer&apos;s disease</title>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">367</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="795" to="804" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Biomarker modeling of Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Jack</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Holtzman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuron</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1347" to="1358" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Fagan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Jasielec</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Dominantly Inherited Alzheimer Network. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer&apos;s disease</title>
	</analytic>
	<monogr>
		<title level="j">Sci Transl Med</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">226</biblScope>
			<biblScope unit="page" from="226" to="230" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Toward defining the preclinical stages of Alzheimer&apos;s disease: recommendations from the National Institute on Aging-Alzheimer&apos;s Association workgroups on diagnostic guidelines for Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Sperling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Aisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Beckett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Alzheimers Dement</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="280" to="292" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Advancing research diagnostic criteria for Alzheimer&apos;s disease: the IWG-2 criteria</title>
		<author>
			<persName><forename type="first">B</forename><surname>Dubois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Feldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jacova</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Neurol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="614" to="629" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Testing the right target and right drug at the right stage</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Sperling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Jack</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Aisen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci Transl Med</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">111</biblScope>
			<biblScope unit="page" from="111" to="133" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Neuropathological diagnostic criteria for Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">S</forename><surname>Murayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Saito</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropathology</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="254" to="260" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Bienias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Wilson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="834" to="841" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Increased total TAU but not amyloid-beta(42) in cerebrospinal fluid correlates with short-term memory impairment in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">Y-T</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-T</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y-C</forename><surname>Yao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Alzheimers Dis</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="907" to="918" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Rowe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rimajova</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurobiol Aging</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1275" to="1283" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Cerebrospinal fluid biomarkers of Alzheimer&apos;s disease in healthy elderly</title>
		<author>
			<persName><forename type="first">C</forename><surname>Randall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mosconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>De Leon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Glodzik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front Biosci (Landmark Ed)</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1150" to="1173" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Klunk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurobiol Aging</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="S20" to="S36" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b42">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Vandenbroucke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Von Elm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration</title>
		<author>
			<persName><surname>Strobe Initiative</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Epidemiology</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="805" to="835" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews</title>
		<author>
			<persName><forename type="first">P</forename><surname>Whiting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Rutjes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Reitsma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Bossuyt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kleijnen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Med Res Methodol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">25</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Mild cognitive impairment as a diagnostic entity</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Petersen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Intern Med</title>
		<imprint>
			<biblScope unit="volume">256</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="183" to="194" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Mild cognitive impairment: beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment</title>
		<author>
			<persName><forename type="first">B</forename><surname>Winblad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Palmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kivipelto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Intern Med</title>
		<imprint>
			<biblScope unit="volume">256</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="240" to="246" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">APOE and Alzheimer disease: a major gene with semi-dominant inheritance</title>
		<author>
			<persName><forename type="first">E</forename><surname>Genin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hannequin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wallon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="903" to="907" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Measuring inconsistency in meta-analyses</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Deeks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">327</biblScope>
			<biblScope unit="issue">7414</biblScope>
			<biblScope unit="page" from="557" to="560" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">G</forename><surname>Chételat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">L</forename><surname>Villemagne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bourgeat</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Relationship between atrophy and beta-amyloid deposition in Alzheimer disease</title>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="317" to="324" />
			<date type="published" when="2010">2010</date>
		</imprint>
		<respStmt>
			<orgName>Australian Imaging Biomarkers and Lifestyle Research Group</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Subjective cognitive complaints and amyloid burden in cognitively normal older individuals</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Amariglio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Carmasin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropsychologia</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2880" to="2886" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Neuropathology of older persons without cognitive impairment from two community-based studies</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Arvanitakis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1837" to="1844" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Medical Research Council Cognitive Function and Ageing Study Investigators. The incidence of dementia in England and Wales: findings from the five identical sites of the MRC CFA Study</title>
		<author>
			<persName><forename type="first">F</forename><surname>Matthews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Brayne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page">e193</biblScope>
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Jack</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Wiste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Weigand</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Neurol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="997" to="1005" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Roe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Xiong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="122" to="131" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">The forgotten APOE allele: a review of the evidence and suggested mechanisms for the protective effect of APOE ε2</title>
		<author>
			<persName><forename type="first">S</forename><surname>Suri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Heise</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Trachtenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Mackay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosci Biobehav Rev</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="2878" to="2886" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">APOE and Alzheimer Disease Meta Analysis Consortium. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Farrer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Cupples</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Haines</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">278</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="1349" to="1356" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis</title>
		<author>
			<persName><forename type="first">F</forename><surname>Liao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hudry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="7281" to="7292" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene</title>
		<author>
			<persName><forename type="first">A</forename><surname>Boehm-Cagan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Michaelson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="7293" to="7301" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Hebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Beckett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1399" to="1405" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Cognitive reserve and Alzheimer disease</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Stern</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Alzheimer Dis Assoc Disord</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="S69" to="S74" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center</title>
		<author>
			<persName><forename type="first">A</forename><surname>Serrano-Pozo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Monsell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Frosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Betensky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">T</forename><surname>Hyman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1182" to="1192" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Medical Research Council Cognitive Function and Ageing Study. Age, neuropathology, and dementia</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Savva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Wharton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Ince</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Forster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Matthews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Brayne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">360</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="2302" to="2309" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
